Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Gilead Sciences, Inc.    GILD   US3755581036


News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

05/11/2012 | 03:06pm US/Eastern
   By Jennifer Corbett Dooren 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

React to this article
Latest news on GILEAD SCIENCES, INC.
12:16p GILEAD SCIENCES : Studies from Gilead Sciences Inc. Provide New Data on Hepatiti..
06/24 GILEAD SCIENCES : Shorter Harvoni Regimen Works for Some, Cutting Costs Without ..
06/19 NEXT LEVEL STOCKS : Biotech ETFs open higher a day after hitting record highs
06/17 GILEAD SCIENCES : to Present at Two Upcoming Investor Conferences on Tuesday, Ju..
06/17 GILEAD SCIENCES : "Tablets for Combination Therapy" in Patent Application Approv..
06/16 GILEAD SCIENCES : EY-Global biotech industry continues to sizzle as market capit..
06/15 GILEAD SCIENCES : MPP, Gilead expand licence to allow generic manufacture of med..
06/12 GILEAD SCIENCES, INC. : ex-dividend day
06/11 GILEAD SCIENCES : Patent Issued for Synthesis of an Antiviral Compound
06/11 GILEAD SCIENCES : Patent Issued for N-Pyrazole A.Sub.2A Receptor Agonists
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Income Statement Evolution
More Financials